Primary Sclerosing Cholangitis - Pipeline Review, H2 2018

  • ID: 4590306
  • Report
  • 111 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Albireo Pharma Inc
  • Allergan Plc
  • Dr. Falk Pharma GmbH
  • DURECT Corp
  • Gilead Sciences Inc
  • MORE
Primary Sclerosing Cholangitis - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2018, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.

Report Highlights:

This latest pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 1, 6 and 1 respectively.

Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Sclerosing Cholangitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acorda Therapeutics Inc
  • Albireo Pharma Inc
  • Allergan Plc
  • Dr. Falk Pharma GmbH
  • DURECT Corp
  • Gilead Sciences Inc
  • MORE
Introduction

Report Coverage

Primary Sclerosing Cholangitis - Overview

Primary Sclerosing Cholangitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Primary Sclerosing Cholangitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development

Acorda Therapeutics Inc

Albireo Pharma Inc

Allergan Plc

Conatus Pharmaceuticals Inc

Dr. Falk Pharma GmbH

DURECT Corp

Gilead Sciences Inc

Intercept Pharmaceuticals Inc

NGM Biopharmaceuticals Inc

Noxopharm Ltd

Sancilio & Company Inc

Seres Therapeutics Inc

Shenzhen HighTide Biopharmaceutical Ltd

Shire Plc

Sirnaomics Inc

Primary Sclerosing Cholangitis - Drug Profiles

A-4250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

berberine ursodeoxycholate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologics for Liver Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenicriviroc - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DUR-928 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9674 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTD-1801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDN-7314 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

maralixibat chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

norursodeoxycholic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NYX-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obeticholic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-435 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Autoimmune Hepatitis and Primary Sclerosing Cholangitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-705 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

timolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Primary Sclerosing Cholangitis - Dormant Projects

Primary Sclerosing Cholangitis - Discontinued Products

Primary Sclerosing Cholangitis - Product Development Milestones

Featured News & Press Releases

Apr 19, 2018 : Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting

Apr 18, 2018 : Conatus Pharmaceuticals IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo

Apr 13, 2018 : NGM Bio Announces Late-Breaking Plenary Presentation At International Liver Conference 2018 Of Detailed Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis

Apr 09, 2018 : Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting

Feb 26, 2018 : DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis

Feb 20, 2018 : DURECT to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC)

Feb 05, 2018 : NGM Reports Top-Line Results From Phase 2 Study Of NGM282 In Patients With Primary Sclerosing Cholangitis (PSC)

Nov 01, 2017: Intercept Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

Oct 23, 2017: Intercept Announces Positive Results from Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis at The Liver Meeting

Oct 20, 2017: Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting

Oct 18, 2017: EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC

Oct 11, 2017: Intercept Announces Data to be Presented at The Liver Meeting

Sep 25, 2017: Intercept Statement Regarding Ocaliva (obeticholic acid) Safety and Dosing in Primary Biliary Cholangitis Patients

Aug 01, 2017: Sirnaomics Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for the Treatment of Primary Sclerosing Cholangitis

Jul 31, 2017: Intercept Announces Positive Results from the Phase 2 AESOP Trial Evaluating OCA for the Treatment of Patients with Primary Sclerosing Cholangitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Primary Sclerosing Cholangitis, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Primary Sclerosing Cholangitis - Pipeline by Acorda Therapeutics Inc, H2 2018

Primary Sclerosing Cholangitis - Pipeline by Albireo Pharma Inc, H2 2018

Primary Sclerosing Cholangitis - Pipeline by Allergan Plc, H2 2018

Primary Sclerosing Cholangitis - Pipeline by Conatus Pharmaceuticals Inc, H2 2018

Primary Sclerosing Cholangitis - Pipeline by Dr. Falk Pharma GmbH, H2 2018

Primary Sclerosing Cholangitis - Pipeline by DURECT Corp, H2 2018

Primary Sclerosing Cholangitis - Pipeline by Gilead Sciences Inc, H2 2018

Primary Sclerosing Cholangitis - Pipeline by Intercept Pharmaceuticals Inc, H2 2018

Primary Sclerosing Cholangitis - Pipeline by NGM Biopharmaceuticals Inc, H2 2018

Primary Sclerosing Cholangitis - Pipeline by Noxopharm Ltd, H2 2018

Primary Sclerosing Cholangitis - Pipeline by Sancilio & Company Inc, H2 2018

Primary Sclerosing Cholangitis - Pipeline by Seres Therapeutics Inc, H2 2018

Primary Sclerosing Cholangitis - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2018

Primary Sclerosing Cholangitis - Pipeline by Shire Plc, H2 2018

Primary Sclerosing Cholangitis - Pipeline by Sirnaomics Inc, H2 2018

Primary Sclerosing Cholangitis - Dormant Projects, H2 2018

Primary Sclerosing Cholangitis - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Primary Sclerosing Cholangitis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acorda Therapeutics Inc
  • Albireo Pharma Inc
  • Allergan Plc
  • Conatus Pharmaceuticals Inc
  • Dr. Falk Pharma GmbH
  • DURECT Corp
  • Gilead Sciences Inc
  • Intercept Pharmaceuticals Inc
  • NGM Biopharmaceuticals Inc
  • Noxopharm Ltd
  • Sancilio & Company Inc
  • Seres Therapeutics Inc
  • Shenzhen HighTide Biopharmaceutical Ltd
  • Shire Plc
  • Sirnaomics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll